Team:Slovenia/Background/The problem

From 2008.igem.org

(Difference between revisions)
 
(35 intermediate revisions not shown)
Line 161: Line 161:
-->
-->
<html><center>
<html><center>
-
<font size="-1" color="#C73E4A"><i><b>The problem</b></i></font>  
+
<font size="6" color="#C73E4A"><i>The problem - infection with <i>Helicobacter pylori</i></i></font>  
</center></html>
</center></html>
----
----
-
VACCINES
+
<html>
-
 
+
<div style="text-align:justify">
-
Vaccines are the single most important application of immunology. Vaccination has saved more lives than any other medical treatment in human history. Generally, typical vaccine is a suspension of microorganisms or parts of microorganisms that induce immune response in the host, either upon injection or via exposure to another portal of entry. Vaccination confers artificially acquired active immunity. A prophylactic vaccine is a vaccine designed to prevent disease. It may be administered prior to exposure to pathogen, or after exposure to pathogen but prior to the occurrence of disease.  
+
<i>Helicobacter pylori</i> are helix-shaped, microaerophilic bacteria with polar flagella that live near the surface of the human gastric mucosa. Approximately half of the world`s population harbors <i>H. pylori</i> in their upper gastrointestinal tract, with 3rd world countries being most affected. There is evidence of co-evolution of human and <i>H. pylori</i>, tracing the migration of human race in the last tens of thousands of years (Covacci et al., 1999).<br />
-
 
+
</div>
-
An ideal vaccine should have the following properties:
+
<p>
-
 
+
      <table width="900" border="0" cellspacing="1" cellpadding="1" align="center">
-
1. safety, ideally 100%;  this is a potential problem with attenuated microbial vaccines,
+
          <tr>
-
 
+
            <td>
-
2. effective in all individuals,
+
              <div align="center">
-
 
+
              <p><img src="https://static.igem.org/mediawiki/2008/6/6d/Pylori1c.jpg" width="350" height="229" /></p>
-
3. effective against wide range of different microbial strains,
+
              </div>
-
 
+
            </td>
-
4. offers long lasting protection without repeated vaccinations,
+
            <td>
-
 
+
            <div align="center">
-
5. stable and simple to store, which is especially important in third world countries,
+
            <p><img src="https://static.igem.org/mediawiki/2008/d/d9/Prevalence.gif" width="450" height="231" /></p>
-
 
+
            </div>
-
6. simple to apply (preferably oral or mucosal application),
+
            </td>
-
 
+
          <tr>
-
7. cheap to manufacture, thus being broadly affordable.
+
          <tr>
-
 
+
            <td>
 +
              <div align="center">
 +
              <p><i>Helicobacter pylori</i></p>
 +
              </div>
 +
            </td>
 +
            <td>
 +
            <div align="center">
 +
            <p> Global prevalence of <i>H. pylori</i> infection</p>
 +
            </div>
 +
            </td>
 +
          <tr>
 +
        </table>
   
   
 +
<div style="text-align:justify">
 +
Infection with <i>H. pylori</i> is usually acquired early in childhood and lasts for a lifetime, and the majority of those infected (80%–90%) remain asymptomatic. However, infection with <i>H. pylori</i> is known to be the strongest risk factor for the development of peptic ulcers. Furthermore, <i>H. pylori</i> was the first bacterium to be classified as a definite carcinogen by the WHO. Thus, from the medical point of view, <i>H. pylori</i> represents a challenging pathogen responsible for much mortality worldwide.
-
There are in principle two types of vaccines:
+
The generally accepted route of transmission for <i>H. pylori</i> is from person to person, e.g. by oral-oral transmission, since <i>H. pylori</i> can only survive for short periods of time because it is rapidly killed by higher oxygen tension and light. Therefore, infection with <i>H. pylori</i> is considered as a "kissing disease".
-
1. whole microbes, which can be either attenuated or killed. This is traditionally the most succesfull type of vaccines. Microbes represent the whole spectrum of antigens and additionally provide microbial adjuvants, that activate innate immune response. Those compounds may, however, be absent from some microbes, which avoid recognition by the immune surveillance such as H. pylori. Attenuated vaccines represent potential danger, particularly in immunocompromised individiuals.
+
Infection with <i>H. pylori</i> can lead to several clinical outcomes. By far the most common gastric phenotype is the »simple gastritis« which is characterized by mild inflammation of the stomach lining and little disruption of gastric acid secretion. The second main phenotype is the duodenal ulcer phenotype (duodenum is the beginning portion of the small intestine) which accounts for up to 15 % in infected subjects. Subjects with this phenotype have defective inhibitory control of gastric acid secretion, which leads to very high acid output and consequently the development of peptic ulcers.<br /><br /><br />
-
2. subunit vaccines, which are isolated or synthetic microbial components, such as proteins or polysaccharides. Genomic information of most microbial pathogens provides a platform to identify the candidate vaccine antigens, in the process called 'reverse vaccinology'. 3D models or structures of antigens provided by structural genomics additionally allow more accurate prediction of the B-cell epitopes of immunodominant antigens, which enable us to design multiepitope vaccines comprising several epitopes from different antigens. Those antigens typically require addition of adjuvants that increase the immune response. Typical adjuvants used for vaccination are aluminium oxides and TLR agonists (CpG, MPLA, poly(I:C)), which trigger production of costimulatory molecules that are required for the development of adaptive immune system. Recent progress in understanding the molecular mechanism of effective adjuvants provides another important step towards more effective vaccines.
+
</div>
 +
<center><img src="https://static.igem.org/mediawiki/2008/5/5f/Ulcer-emergencies1.gif" width="400" height="320" border="0" />
 +
<br />
 +
<br />
 +
If untreated, peptic ulcers can commonly result in haemorrhage into the <br />
 +
stomach or the abdominal cavity which often leads to severe blood loss <br />
 +
and even death.<br />
 +
<font size="1">Image from http://medicalimages.allrefer.com/large/ulcer-emergencies. jpg</font>
 +
</center>
 +
<div style="text-align:justify">
 +
<br />
 +
The third and most serious phenotype is the »gastric cancer phenotype«, which is, in contrast to the previous two phenotypes, characterized with hypo- or achlorhydria (low acid secretion) and affects up to 5% of infected subjects. Gastric cancer is a formidable disorder, primarily because most patients are diagnosed at an advanced stage of disease. Despite the curative surgical resection vast majority of affected individuals often die of recurrent disease. 
 +
<br /><br /> 
 +
Interestingly, <i>H. pylori</i> is the only known organism capable of colonizing the severe environment of the human stomach, but even this bacterium can withstand low pH for only short periods of time. <i>H. pylori</i> has developed several mechanisms to avoid bactericidal activity of HCl. It uses its polar flagella for motility in chemotactic response to pH gradient, by which it stays in close proximity to the surface of the epithelium, where pH is near neutral. Besides that, <i>H. pylori</i> was shown to be capable of adhering to the surface and even invading the epithelial cells so as to protect itself from gastric contents and mechanical clearance to promote perseverance. <i>H. pylori</i> also possesses artificial means of increasing pH in its direct proximity by generating large quantities of cytosolic and cell surface-associated urease, an enzyme capable of the breakdown of urea into ammonia and carbon dioxide.
 +
<br /><br /> 
 +
Alongside the capability of breaching the cellular and physical barriers, <i>H. pylori</i> has additionally developed ways of avoiding both the innate and the adaptive immune response of the host organism. To date, several bacterial strategies have been described (some of them are illustrated in table and figure below). For example, <i>H. pylori</i> flagellar proteins have developed in a way that masks them from the Toll-like receptor 5 (an innate immune receptor, that recognizes various other bacterial flagellins). LPS from <i>H. pylori</i> is 1000 times less pyrogenic and 500-fold less toxic than that of gram-negative enteric bacteria due to modifications that mimic human glycans and therefore induces less inflammation. <i>H. pylori</i> is also capable of obtaining cholesterol directly from epithelial cell membranes and incorporating it into its own lipid layer. To escape macrophage phagocytosis it modifies obtained cholesterol by adding a glucosyl group (a reaction catalysed by cholesterol-α glucosyltransferase). Additionally, <i>H. pylori</i> reduces generation of bactericidal nitric oxide by the macrophage. Its enzyme arginase competes with macrophages inducible nitric oxide synthase for substrate L-arginine that is used by the bacteria for the synthesis of urea (a substrate for urease). Moreover, exposure to <i>H. pylori</i> products upregulates transcription of arginase II in macrophages, which catalyses breakdown of L-arginine into urea and L-ornithine that is subsequently metabolized into polyamines that trigger apoptosis in macrophages.
 +
<br /><br />
   
   
 +
</div>
 +
<left><img src="https://static.igem.org/mediawiki/2008/b/b7/Kon%C4%8Dna_evasion_2_copy.jpg" width="600" height="449" border="0" />
 +
<br />
 +
<br />
 +
<left><font size="2"><span style="font-size: 100%; text-align:justify">
 +
<i>Helicobacter pylori</i> modifies its LPS and flagellin so that they do not activate Toll-like receptors 4 and 5<br />
 +
opposite to LPS and flagellin of <i>Escherichia coli</i>),  which results in no activation of the immune system cells.
 +
<br /><br /><br />
 +
Summary of strategies that <i>H. pylori</i> employs to avoid detection of the immune system
 +
</span></font></strong></html>
   
   
 +
<html>
 +
<table border="1" cellpadding="0" cellspacing="0">
 +
<tbody>
 +
<tr>
 +
<td style="border: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <strong><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">MECHANISM</font></span></span></strong></td>
 +
<td style="border-color: black black black rgb(236, 233, 216); border-top: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339">  <strong><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">EXAMPLE</font></span></span></strong></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Bypassing the TLR system</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">-&nbsp;Flag</font></span></span><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">ellin fails to activate TLR5&nbsp;</font> <font color="#000000">(Gewirtz et al., 2004)<br></font></span></span><span style="background-color: rgb(255, 255, 255);"><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">-</font> <span style="color: black;">Tetraacylated LPS poorly activates TLR4 and may actually work as an antagonist</span> <span style="color: black;">(Moran and Aspinall, 1998)<br></span></span></span></span><span style="background-color: rgb(255, 255, 255);"><span style="font-family: Arial;"><span style="font-size: 10pt; color: black;">- DNA&nbsp;is rich in A/T nucleotides and frequently methylated, making TLR9 response more unprobable (Blaser and Atherton, 2004)</span></span></span></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Minimization of innate immunity</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Modification of LPS (<span style="color: black;">long 3-hydroxy fatty acids of lipid A, unusual phosphorylation pattern…)</span> <span style="background-color: rgb(255, 255, 255);"><span style="color: black;">(Moran et al., 1997, 1998)</span></span></font></span></span></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Mimicry of host antigens</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Lewis expression (</font><span style="color: black;">O antigen region of <i>H. pylori</i> LPS)</span> <span style="background-color: rgb(255, 255, 255);"><span style="color: black;">(Wirth et al., 1997)</span></span></span></span></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Antigenic variation</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Cag</font><span style="background-color: rgb(255, 255, 255);"><font color="#000000">Y (Aras et al., 2003)</font></span></span></span></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Host gene expression modulation</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339">  <span style="font-family: Arial;"><span style="font-size: 10pt; color: black;">- Upregulation of specific inflammatory and immune mediators including β-defensin, protease inhibitor, chemokine rec</span><span style="background-color: rgb(255, 255, 255);"><span style="font-size: 10pt; color: black;">eptor, interleukin-1β, tumor necrosis factor-α-inducible protein… (Israel and Peek, 2006)</span></span></span></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Downregulation of immune effectors</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><span style="font-family: Arial;"><span style="font-size: 10pt; color: black;">- Blocking the proliferation of T cell through VacA</span> <span style="font-size: 10pt;"><span><font color="#000000">&nbsp;</font></span><span style="color: black;">and<span>&nbsp;</span>B cell proliferation<span>&nbsp;</span> through Cag</span></span></span><span style="font-family: Arial;"><span style="font-size: 10pt;"><span style="color: black;">A-induced supression</span></span></span><span style="background-color: rgb(255, 255, 255);"><span style="font-family: Arial;"><span style="font-size: 10pt; color: black;">- Interference with phagocytosis</span> <span style="font-size: 10pt; color: black;">(Baldari et al., 2005)</span></span></span></td>
 +
</tr>
 +
<tr>
 +
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Avoidance of attack by ROIs and RNIs</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Enzymes involved in ROI scavenging, such as catalase and superoxide dismutase<br></font></span></span><span style="background-color: rgb(255, 255, 255);">&nbsp;</span><span style="background-color: rgb(255, 255, 255);"><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Arginase regulates NO synthesis <span style="color: black;">(Baldari et al., 2005)</span></font></span></span></span></td>
 +
</tr>
 +
<tr>
-
MODERN VACCINES
+
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">Ability to colonize gastric environment</font></span></span></td>
-
 
+
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Neutralizing pH around the organism with urease enzyme<br></font></span></span><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Interaction between adhesins and<span>&nbsp;</span>local cell receptors<br></font></span></span><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Expressing mucolytic molecules<br></font></span></span><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Relative absence of immune cells in gastric mucosa and rare competition with commensal bacteria</font></span></span></td>
-
+
</tr>
-
 
+
<tr style="height: 46.55pt;">
-
Generally, an effective vaccine should induce an innate immune response, high titters of neutralizing antibodies, strong cellular immune response, including activation of T helper cells and cytotoxic T lymphocytes (CTLs), as well as mucosal immune response. This should lead to a long lasting protection against infections. The consequence of the progress in basic immunology resulted in understanding of a cooperation between innate and adaptive immunity .
+
-
 
+
-
Defined essential signals are required to induce effective T and B cell responses and subsequent establishing of memory T and B cell repertoires, which is the aim of vaccination. Briefly, these signals are: antigen recognition and APC activation, antigen presentation and costimulation.
+
-
 
+
-
The role of costimulation in T cell activation explains an old observation that protein antigens fail to elicit T cell-dependent immune response unless these antigens are administered with substances that activate dendritic cells, macrophages and other APCs. This has been called the 'dirty little secret of immunologists', and today we know that this effect was due to adjuvants. The term is derived from the latin adjuvare, meaning to help, because these compounds can increase and/or modulate the intrinsic immunogenicity of an antigen by inducing the expression of costimulators on APCs and by stimulating the APCs to secrete cytokines that activate T cells. Adjuvants convert inert protein antigens into mimics of pathogenic microbes (Guy B. 2007).
+
-
 
+
-
+
-
 
+
-
Most adjuvants actually belong to pathogen-associated molecular patterns (PAMPs), molecules that are recognized by innate immune cells by specific pathogen recognition receptors (PRRs). Among PRRs, TLRs play a crucial role in early steps of immune response to infection. TLRs are expressed at the surface or in the endosomes of different APC subtypes and they respond to specific bacterial, viral, fungal or protozoan signals. This activates APCs, modulates and shapes the adaptive response, for instance, by shifting the balance towards Th1 or Th2 cells. Importantly, TLRs do not only trigger APC activation, but they also have a role in antigen presentation. The presence of both antigen and TLR is required for optimal antigen presentation and activation: TLRs control the generation of T-cell receptor (TCR) ligands (peptides, derived from processing of pathogen antigens, bound to MHC class 2 molecules) from the phagosome, which ensures that the contents derived from microbial pathogens are preferentially presented to T cells by the activated APC. This means that antigen and TLR-agonists should be co-delivered in order to be present in the same phagosome cargo and induce optimal antigen presentation and stimulation of the subsequent T cell response (Blander J.M., 2007).
+
-
 
+
-
+
-
 
+
-
The identification of chemical nature of TLR agonists has led to the design of synthetic ligands that can trigger TLRs more precisely and safely than pathogen-derived ligands, which were selected by their ability to bind receptors and activate downstream signalling pathways. Different PRR agonists can synergize and/or balance each other’s immunomodulatory activity. It is known, that we can induce sinergy by combining agonists that act on MyD88-dependent and MyD88-independent pathways. A vaccine that stimulates complementary TLR pathways can thus broaden the Th-cell response that is induced.
+
-
 
+
-
Perfect example of sinergy is the live attenuated yellow fever vaccine 17D (YF-17D), that is one of the most effective vaccines available. Immunological mechanisms, by which YF-17D acts were recently revealed by Querec et. al.  This vaccine activates multiple TLRs on dendritic cells to elicit a broad spectrum of innate and adaptive immune respones. Specifically it activates multiple DC subsets via TLRs 2, 7 ,8 and 9. The adaptive immune response is charactereized by a mixed T helper cell Th1/Th2 cytokine profile and antigen-specific CD8+ T cells.
+
-
 
+
-
+
-
 
+
-
TLR agonists, that polarize immune response towards Th1 are LPS (TLR 4 agonist), flagellin (TLR 5 agonist), dsRNA (TLR 3 agonist), ssRNA (TLR 7 and TLR 8 agonist) and unmethyated DNA (TLR 9 agonist). Contrary, Th2 inducers are triacyl lipopeptides (TLR 1-2 agonist) and diacyl lipopeptide (TLR 2-6 agonist).
+
-
 
+
-
+
-
 
+
-
Rational design of modern vaccines is the promising way to find the optimal and safe formulation of adjuvants and antigens, that will work synergisticly and elicit desired immune response. New vaccines have more defined composition and always include adjuvants, that mimic and compensate lacking pathogen's properties, that are needed to induce immune response.
+
-
 
+
-
+
-
 
+
-
+
-
 
+
-
Schematic diagram of human Toll-like receptors, their ligands, adaptor molecules and cellular localization
+
-
 
+
-
(Kanzler H., 2007)
+
-
 
+
-
+
-
 
+
-
 
+
-
 
+
-
<html>  
+
<td style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; height: 46.55pt; background-color: transparent;" valign="top" width="168">  <span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">High mutational and recombinational frequency, high diversity</font></span></span></td>
 +
<td style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; height: 46.55pt; background-color: transparent;" valign="top" width="339"><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- Rapid development in the bacterial population of high-level resistance to commonly used antibiotics<br></font></span></span><span style="font-family: Arial;"><span style="font-size: 10pt;"><font color="#000000">- High competence for uptake of DNA from other <i>H. pylori</i> strains</font> <span style="background-color: rgb(255, 255, 255);"><font color="#000000">(Sansonetti and Di Santo, 2007)</font></span></span></span></td>
 +
</tr>
 +
</tbody>
 +
</table>
 +
<br />
 +
<div style="text-align:justify">
 +
There is also experimental evidence linking bacterial adhesion and disease progression as an outcome of delivery of toxins, for instance VacA (pore-forming cytotoxin) that is characterized as a potent inhibitor of T-cell function and believed to be capable of inserting into the membranes of late endosomal vesicles to perturb antigen presentation. VacA can also disrupt the barrier function of tight junctions and thereby causes leakage of ions and small molecules from host cells, so that <i>H. pylori</i> can acquire nutrients across an intact epithelial barrier.
 +
<br /><br />
 +
Current medical treatment of peptic ulcers and <i>H. pylori</i> infection consists mainly of three- and four-drug regimes, which combine two antibiotics with either proton pump inhibitors to reduce the production of gastric acid and/or cytoprotective agents that protect cells from toxic chemicals or other stimuli. Although these regimes are very effective at eradicating <i>H. pylori</i> with cure rates higher than 90%, there remains a serious problem of increasing antibiotic resistance. In addition, re-infection with <i>H. pylori</i> after antimicrobal therapy occurs frequently in countries where infection rates are high. Therefore, the only way to effectively prevent <i>H. pylori</i> (re)infection seems to be through long-term vaccination programs.
 +
<br /><br />
 +
In the past 25 years since <i>H. pylori</i> has been first described and cultured, more than 20.000 publications have appeared on the subject. Understanding how this organism interacts with its host is of fundamental importance for preparation an intelligent strategy to prevent and cure <i>H. pylori</i> infections. To date, some promising approaches in vaccine development have been tested but still an effective vaccine against <i>H. pylori</i> remains to be demonstrated. Current knowledge of immunology, especially TLR activation and subsequent signaling, has enabled our team to design and test out some innovative ideas in vaccine development.
 +
<br /><br />
 +
</div>
</p>
</p>
</td>
</td>

Latest revision as of 03:59, 30 October 2008

Igem-logo-900x200-1-2.jpg



The problem - infection with Helicobacter pylori



Helicobacter pylori are helix-shaped, microaerophilic bacteria with polar flagella that live near the surface of the human gastric mucosa. Approximately half of the world`s population harbors H. pylori in their upper gastrointestinal tract, with 3rd world countries being most affected. There is evidence of co-evolution of human and H. pylori, tracing the migration of human race in the last tens of thousands of years (Covacci et al., 1999).

Helicobacter pylori

Global prevalence of H. pylori infection

Infection with H. pylori is usually acquired early in childhood and lasts for a lifetime, and the majority of those infected (80%–90%) remain asymptomatic. However, infection with H. pylori is known to be the strongest risk factor for the development of peptic ulcers. Furthermore, H. pylori was the first bacterium to be classified as a definite carcinogen by the WHO. Thus, from the medical point of view, H. pylori represents a challenging pathogen responsible for much mortality worldwide. The generally accepted route of transmission for H. pylori is from person to person, e.g. by oral-oral transmission, since H. pylori can only survive for short periods of time because it is rapidly killed by higher oxygen tension and light. Therefore, infection with H. pylori is considered as a "kissing disease". Infection with H. pylori can lead to several clinical outcomes. By far the most common gastric phenotype is the »simple gastritis« which is characterized by mild inflammation of the stomach lining and little disruption of gastric acid secretion. The second main phenotype is the duodenal ulcer phenotype (duodenum is the beginning portion of the small intestine) which accounts for up to 15 % in infected subjects. Subjects with this phenotype have defective inhibitory control of gastric acid secretion, which leads to very high acid output and consequently the development of peptic ulcers.




If untreated, peptic ulcers can commonly result in haemorrhage into the
stomach or the abdominal cavity which often leads to severe blood loss
and even death.
Image from http://medicalimages.allrefer.com/large/ulcer-emergencies. jpg

The third and most serious phenotype is the »gastric cancer phenotype«, which is, in contrast to the previous two phenotypes, characterized with hypo- or achlorhydria (low acid secretion) and affects up to 5% of infected subjects. Gastric cancer is a formidable disorder, primarily because most patients are diagnosed at an advanced stage of disease. Despite the curative surgical resection vast majority of affected individuals often die of recurrent disease.

Interestingly, H. pylori is the only known organism capable of colonizing the severe environment of the human stomach, but even this bacterium can withstand low pH for only short periods of time. H. pylori has developed several mechanisms to avoid bactericidal activity of HCl. It uses its polar flagella for motility in chemotactic response to pH gradient, by which it stays in close proximity to the surface of the epithelium, where pH is near neutral. Besides that, H. pylori was shown to be capable of adhering to the surface and even invading the epithelial cells so as to protect itself from gastric contents and mechanical clearance to promote perseverance. H. pylori also possesses artificial means of increasing pH in its direct proximity by generating large quantities of cytosolic and cell surface-associated urease, an enzyme capable of the breakdown of urea into ammonia and carbon dioxide.

Alongside the capability of breaching the cellular and physical barriers, H. pylori has additionally developed ways of avoiding both the innate and the adaptive immune response of the host organism. To date, several bacterial strategies have been described (some of them are illustrated in table and figure below). For example, H. pylori flagellar proteins have developed in a way that masks them from the Toll-like receptor 5 (an innate immune receptor, that recognizes various other bacterial flagellins). LPS from H. pylori is 1000 times less pyrogenic and 500-fold less toxic than that of gram-negative enteric bacteria due to modifications that mimic human glycans and therefore induces less inflammation. H. pylori is also capable of obtaining cholesterol directly from epithelial cell membranes and incorporating it into its own lipid layer. To escape macrophage phagocytosis it modifies obtained cholesterol by adding a glucosyl group (a reaction catalysed by cholesterol-α glucosyltransferase). Additionally, H. pylori reduces generation of bactericidal nitric oxide by the macrophage. Its enzyme arginase competes with macrophages inducible nitric oxide synthase for substrate L-arginine that is used by the bacteria for the synthesis of urea (a substrate for urease). Moreover, exposure to H. pylori products upregulates transcription of arginase II in macrophages, which catalyses breakdown of L-arginine into urea and L-ornithine that is subsequently metabolized into polyamines that trigger apoptosis in macrophages.



Helicobacter pylori modifies its LPS and flagellin so that they do not activate Toll-like receptors 4 and 5
opposite to LPS and flagellin of Escherichia coli), which results in no activation of the immune system cells.


Summary of strategies that H. pylori employs to avoid detection of the immune system

MECHANISM EXAMPLE
Bypassing the TLR system - Flagellin fails to activate TLR5  (Gewirtz et al., 2004)
- Tetraacylated LPS poorly activates TLR4 and may actually work as an antagonist (Moran and Aspinall, 1998)
- DNA is rich in A/T nucleotides and frequently methylated, making TLR9 response more unprobable (Blaser and Atherton, 2004)
Minimization of innate immunity - Modification of LPS (long 3-hydroxy fatty acids of lipid A, unusual phosphorylation pattern…) (Moran et al., 1997, 1998)
Mimicry of host antigens - Lewis expression (O antigen region of H. pylori LPS) (Wirth et al., 1997)
Antigenic variation CagY (Aras et al., 2003)
Host gene expression modulation - Upregulation of specific inflammatory and immune mediators including β-defensin, protease inhibitor, chemokine receptor, interleukin-1β, tumor necrosis factor-α-inducible protein… (Israel and Peek, 2006)
Downregulation of immune effectors - Blocking the proliferation of T cell through VacA  and B cell proliferation  through CagA-induced supression- Interference with phagocytosis (Baldari et al., 2005)
Avoidance of attack by ROIs and RNIs - Enzymes involved in ROI scavenging, such as catalase and superoxide dismutase
 - Arginase regulates NO synthesis (Baldari et al., 2005)
Ability to colonize gastric environment - Neutralizing pH around the organism with urease enzyme
- Interaction between adhesins and local cell receptors
- Expressing mucolytic molecules
- Relative absence of immune cells in gastric mucosa and rare competition with commensal bacteria
High mutational and recombinational frequency, high diversity - Rapid development in the bacterial population of high-level resistance to commonly used antibiotics
- High competence for uptake of DNA from other H. pylori strains (Sansonetti and Di Santo, 2007)

There is also experimental evidence linking bacterial adhesion and disease progression as an outcome of delivery of toxins, for instance VacA (pore-forming cytotoxin) that is characterized as a potent inhibitor of T-cell function and believed to be capable of inserting into the membranes of late endosomal vesicles to perturb antigen presentation. VacA can also disrupt the barrier function of tight junctions and thereby causes leakage of ions and small molecules from host cells, so that H. pylori can acquire nutrients across an intact epithelial barrier.

Current medical treatment of peptic ulcers and H. pylori infection consists mainly of three- and four-drug regimes, which combine two antibiotics with either proton pump inhibitors to reduce the production of gastric acid and/or cytoprotective agents that protect cells from toxic chemicals or other stimuli. Although these regimes are very effective at eradicating H. pylori with cure rates higher than 90%, there remains a serious problem of increasing antibiotic resistance. In addition, re-infection with H. pylori after antimicrobal therapy occurs frequently in countries where infection rates are high. Therefore, the only way to effectively prevent H. pylori (re)infection seems to be through long-term vaccination programs.

In the past 25 years since H. pylori has been first described and cultured, more than 20.000 publications have appeared on the subject. Understanding how this organism interacts with its host is of fundamental importance for preparation an intelligent strategy to prevent and cure H. pylori infections. To date, some promising approaches in vaccine development have been tested but still an effective vaccine against H. pylori remains to be demonstrated. Current knowledge of immunology, especially TLR activation and subsequent signaling, has enabled our team to design and test out some innovative ideas in vaccine development.